Search
forLearn
5 / 801 resultslearn TDM-105795
learn Tricopper peptides
learn Coenzyme Q10
learn medium chain triglycerides
Research
5 / 22 resultsresearch 3D Spheroid Human Dermal Papilla Cell as an Effective Model for the Screening of Hair Growth Promoting Compounds: Examples of Minoxidil and 3,4,5-Tri-O-Caffeoylquinic Acid (TCQA)
3D cell cultures are better for testing hair growth treatments than 2D cultures.
research 3D Spheroid Human Dermal Papilla Cell as an Effective Model for the Screening of Hair Growth Promoting Compounds: Examples of Minoxidil and 3,4,5-Tri-O-caffeoylquinic acid (TCQA)
3D spheroid cells effectively test hair growth compounds like Minoxidil.
research Establishment of 3D Spheroid Human Dermal Papilla Cells as an Effective Model for Hair Growth Screening Compounds Compared with the 2D System: An Example of Minoxidil and 3,4,5-Tri-O-caffeoylquinic acid (TCQA)
3D spheroid cultures of human hair follicle cells are better for hair growth research than 2D cultures, and they provide new insights into how hair growth treatments like minoxidil and TCQA work.
research β-catenin-mediated hair growth induction effect of 3,4,5-tri-O-caffeoylquinic acid
3,4,5-tri-O-caffeoylquinic acid promotes hair growth by activating the β-catenin pathway.
research 3,4,5-Tri-O-Caffeoylquinic Acid Promoted Hair Pigmentation Through β-Catenin and Its Target Genes
A substance called TCQA could potentially darken hair by activating certain genes and increasing melanin.
Community Join
5 / 1000+ resultscommunity Post TCA pic and two month in, just posting baseline and an update.
The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Phase II Clinical Trial for TDM-105795 started recruiting
A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.